From Crypto to Cytoplasm: Brian Armstrong’s NewLimit Targets Hepatocytes for Anti-Aging Breakthrough

In a biotech landscape often preoccupied with the elusive fountain of youth, a new strategy is emerging: tackle aging one organ at a time. The latest example is NewLimit – a California startup co-founded by Coinbase CEO Brian Armstrong – which just raised an eye-popping $130 million Series B round to advance an mRNA-based therapy aimed at rejuvenating liver cells. Rather than pursuing a nebulous “anti-aging” miracle for the whole body, NewLimit is zeroing in on the liver, betting that making this vital organ biologically younger can be a first step toward extending healthy lifespan. The company’s approach, using lipid nanoparticle (LNP) delivery of mRNA encoding youthful transcription factors,

 » Read More